Key facts
- This page summarizes Jennifer Marlowe's Form 4 filing for Solid Biosciences Inc. (SLDB).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 05 Dec 2023, 14:30.
Jennifer Marlowe - 02 Dec 2023 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)
- Reporting relationship
- CSO
- Issuer ticker
- SLDB
- Reported as of
- 02 Dec 2023
- Net transaction value
- -$13,525
- SEC form
- 4
- Accepted by SEC
- 05 Dec 2023, 14:30:05 UTC
- Prior SEC filing
- 05 Dec 2022
- Next SEC filing
- 16 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Tyronne Howton as attorney-in-fact for Jennifer Marlowe
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jennifer Marlowe filed Form 4 for Solid Biosciences Inc. (SLDB) on 05 Dec 2023.
Change
- Previous filing in this sequence was filed on 05 Dec 2022.
- Current net transaction value: -$13,525.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SLDB
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +11,888
- Change %
- Price
- Shares after
- 11,888
- Date
- 02 Dec 2023
- Ownership
- Direct
- Footnotes
- F1
SLDB
transaction
Common Stock
Sale
- Transaction value
- $13,525
- Shares
- -4,890
- Change %
- -41%
- Price
- $2.77
- Shares after
- 6,998
- Date
- 04 Dec 2023
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SLDB
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -11,888
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 35,667
- Date
- 02 Dec 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,888
- Exercise price
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").
Footnote F2
This sale was made to cover withholding taxes following the vesting of the previously granted RSUs. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1).
Footnote F3
The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.